Kezar CEO Christopher Kirk Exits All Holdings After Aurinia Cash-and-CVR Tender

Context Aurinia Pharma U.S., Inc. launched a cash‑and‑contingent value right (CVR) tender offer for Kezar common shares under a March 30, 2026 merger agreement. Each tendered share received $6.955 in cash after taxes plus one CVR that pays only if Aurinia meets predefined milestones. In‑the‑money employee stock options were converted to cash based on the spread over the cash amount, while out‑of‑the‑money options were cancelled with no consideration.

Key Facts The filing shows Kirk disposed of 43,134 Kezar shares at $6.955 cash per share. Simultaneously, he relinquished options covering hundreds of thousands of shares at exercise prices ranging from $5.58 to $59.10, all settled per the merger terms. After these transactions, his direct holdings of Kezar stock and options are zero. Market data: Kezar (NASDAQ: KZR) closed at $6.80, down 4.2% on the day, with a market cap of roughly $210 million; Aurinia (NASDAQ: AUPH) closed at $17.30, up 1.1%, valued near $4.2 billion; the NASDAQ Biotechnology Index rose 0.5%.

What It Means The CEO’s exit removes a significant insider stake, potentially reducing alignment between leadership and shareholders. The CVRs remain non‑tradable and contingent, so any future value depends on Aurinia achieving milestone payments. Investors should monitor milestone announcements and any subsequent insider transactions for signals about confidence in the combined entity.

Watch for the first milestone trigger under the CVR agreement, which could generate cash payments to former Kezar shareholders and clarify the long‑term value of the deal.